Skip to content
Contact Us
About
Leadership
Board of Directors
Scientific Advisory Board
Science & Tech
Vorolanib
DURASERT® Technology
VERISOME® Technology
Partnerships and BD Initiatives
Pipeline & Data
Pipeline
EYP-1901
Overview
Clinical Trials
Scientific Publications and Presentations
EYP-2301
Investors
Financial Information
Financials Overview
Stock Information
Analyst Coverage
Ownership Summary
Annual Reports
Earnings Releases
SEC Filings
Resources
Press Releases
Events & Presentations
IR Contact
Email Alerts
Corporate Governance
Governance Overview
Management Team
Board of Directors
Committee Composition
Contact the Board
FAQs
Form 8937
News
Careers
About
Leadership
Board of Directors
Scientific Advisory Board
Science & Tech
Vorolanib
DURASERT® Technology
VERISOME® Technology
Partnerships and BD Initiatives
Pipeline & Data
Pipeline
EYP-1901
Overview
Clinical Trials
Scientific Publications and Presentations
EYP-2301
Investors
Financial Information
Financials Overview
Stock Information
Analyst Coverage
Ownership Summary
Annual Reports
Earnings Releases
SEC Filings
Resources
Press Releases
Events & Presentations
IR Contact
Email Alerts
Corporate Governance
Governance Overview
Management Team
Board of Directors
Committee Composition
Contact the Board
FAQs
Form 8937
News
Careers
Home
About
Science & Tech
Pipeline & Data
Investors
News
Careers
Contact Us
Menu
Home
About
Science & Tech
Pipeline & Data
Investors
News
Careers
Contact Us
EyePoint in the News
EyePoint In The News
Ophthalmology Breaking News
EyePoint Pharmaceuticals Appoints Jay S. Duker as the New CEO
07/11/2023
Healio Ocular Surgery News
Enrollment complete in EyePoint phase 2 nonproliferative diabetic retinopathy trial
06/07/2023
Boston Business Journal
EyePoint licenses inflammation drug to Atlanta firm for $82.5M
05/18/2023
